CAMBRIDGE, Mass. -- (BUSINESS WIRE) -- BIND Therapeutics, Inc. (NASDAQ: BIND) a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called AccurinsTM, announced today that it will report financial results for the third quarter ended September 30, 2013 on Tuesday, November 5, 2013. BIND’s management team will host a conference call and audio webcast at 8:30 a.m., Eastern Time, on Tuesday, November 5, 2013 to discuss the quarterly results and recent business developments.
To access the conference call, please dial 877-312-5844 (domestic) or 253-237-1152 (international) at least five minutes prior to the start time and refer to conference ID 83773670. A live audio webcast of the call will also be available on the Investors & Media section of the company's website, www.bindtherapeutics.com. An archived webcast will be available on the Company’s website approximately two hours after the event.
About BIND Therapeutics
BIND Therapeutics is a clinical-stage nanomedicine platform company developing Accurins, its novel targeted therapeutics. BIND intends to leverage its medicinal nanoengineering platform to develop a pipeline of Accurins, initially in oncology, as well as Accurins in collaboration with biopharmaceutical companies. BIND's lead drug candidate, BIND-014, is an Accurin that targets PSMA and contains docetaxel, a clinically-validated and widely used cancer chemotherapy drug. BIND-014 is currently in Phase 2 clinical trials for non-small cell lung cancer and metastatic castrate resistant prostate cancer.
To date in 2013, BIND has announced collaborations with Amgen, Inc., Pfizer Inc. and AstraZeneca AB to develop Accurins based on therapeutic payloads from their product pipelines. BIND’s platform originated from the pioneering nanotechnology research at the Massachusetts Institute of Technology and Brigham and Women’s Hospital/Harvard Medical School of BIND’s scientific founders and directors Dr. Robert Langer and Dr. Omid Farokhzad. For more information, please visit the company's web site at www.bindtherapeutics.com.